Odyssey
  • Homepage
  • Objectives
  • News
  • Publications
  • Privacy
    • Privacy Policy
    • Cookie Policy
  • Contact
  • Restricted
Select Page

ODYSSEY: design, current status, and baseline characteristics

by Communication Team | Jan 27, 2020 | Publication

Authors: Moore CL,  Kekitinwa A, Kaudha E, et al; the ODYSSEY Trial TeamPublished in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018. Poster Number 34 Download

Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing 14 to <25kg on film-coated dolutegravir 25mg tablets

by Communication Team | Jan 27, 2020 | Publication

Authors: Bollen P, Turkova A, Hilda Mujuru H, et al. The ODYSSEY Trial TeamPublished in: 10th International Workshop on HIV Pediatrics, Amsterdam, 20-21st July 2018. Poster Number 22 Download

Adult dolutegravir 50mg film-coated tablets in children living with HIV weighing 20 to <25 kg

by Communication Team | Jan 27, 2020 | Publication

Authors: Bollen P, Turkova A, Mujuru H, et al. for the ODYSSEY Trial Team Published in: 26th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2019– Seattle. P_830 Download

Pharmacokinetics of dolutegravir 5mg dispersible tablets in children weighing 6 to <20kg dosed using WHO weight bands

by odysseyadmin | Jan 24, 2020 | Publication

Authors: Waalewijn H, Bollen PDJ, Moore C, Kekitiinwa A, et al. The ODYSSEY Trail TeamPublished in: Oral Presentation at 10th IAS Conference, July, 21-24th 2019 Download

Analysing small groups within clinical trials, while borrowing information from larger groups

by odysseyadmin | Jan 24, 2020 | Publication

Authors: Turner B, Ford D, Moore C, Gibb D, Turkova A,  White I, and ODYSSEY trial teamPublished in: Oral Presentation atInternational Society for Clinical Biostatics; July 16th 2019 Download

Recent Posts

  • Cheaper HIV treatment for children: a report in the Lancet
  • European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV
  • ODYSSEY trial data published in Lancet – shows increase in treatment options for older children living with HIV
  • Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
  • Dolutegravir for Children living with HIV

Recent Comments

    Archives

    • December 2020
    • November 2020
    • August 2020
    • June 2020
    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • March 2019
    • July 2018
    • June 2018
    • April 2018
    • August 2017
    • September 2016

    Categories

    • ODYSSEY
    • Publication

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    This study is funded by ViiV Healthcare and the sponsor is PENTA Foundation